ABVC BioPharma, Inc. (ABVC)
NASDAQ: ABVC · Real-Time Price · USD
2.410
-0.120 (-4.74%)
Dec 5, 2025, 4:00 PM EST - Market closed
ABVC BioPharma Income Statement
Financials in millions USD. Fiscal year is January - December.
Millions USD. Fiscal year is Jan - Dec.
Fiscal Year | TTM | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | 2015 - 2019 |
|---|---|---|---|---|---|---|---|
Period Ending | Sep '25 Sep 30, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 | Dec '20 Dec 31, 2020 | 2015 - 2019 |
| Revenue | 0.8 | 0.51 | 0.15 | 0.97 | 0.36 | 0.48 | Upgrade
|
| Revenue Growth (YoY) | 56.52% | 234.31% | -84.28% | 172.57% | -26.34% | -31.16% | Upgrade
|
| Cost of Revenue | - | 0 | 0.3 | 0.29 | 0.01 | 0.02 | Upgrade
|
| Gross Profit | 0.8 | 0.51 | -0.15 | 0.68 | 0.35 | 0.46 | Upgrade
|
| Selling, General & Admin | 2.42 | 2.26 | 5.37 | 6.07 | 5.75 | 4.27 | Upgrade
|
| Research & Development | 0.12 | 0.18 | 1.06 | 2.69 | 1 | 0.55 | Upgrade
|
| Operating Expenses | 5.71 | 5.21 | 6.62 | 15.8 | 12.06 | 8.97 | Upgrade
|
| Operating Income | -4.91 | -4.71 | -6.77 | -15.11 | -11.71 | -8.51 | Upgrade
|
| Interest Expense | -0.6 | -0.83 | -1.31 | -0.29 | -0.23 | -0.41 | Upgrade
|
| Interest & Investment Income | 0.1 | 0.09 | 0.19 | 0.19 | 0.04 | 0.07 | Upgrade
|
| Currency Exchange Gain (Loss) | -0.04 | -0.03 | 0.02 | -0.26 | 0.43 | -0 | Upgrade
|
| Other Non Operating Income (Expenses) | 0.2 | 0.18 | 0.07 | 0.08 | 0.16 | 0.2 | Upgrade
|
| EBT Excluding Unusual Items | -5.25 | -5.29 | -7.8 | -15.4 | -11.3 | -8.64 | Upgrade
|
| Gain (Loss) on Sale of Investments | -0.34 | -0.34 | -0.22 | -0.01 | -0.27 | -2.17 | Upgrade
|
| Asset Writedown | - | - | - | -0.11 | - | - | Upgrade
|
| Other Unusual Items | 0.26 | 0.26 | - | - | 0.36 | - | Upgrade
|
| Pretax Income | -5.34 | -5.37 | -8.02 | -15.51 | -11.21 | -10.81 | Upgrade
|
| Income Tax Expense | 0.02 | -0.11 | 0.26 | 0.8 | 0.83 | -0.22 | Upgrade
|
| Earnings From Continuing Operations | -5.36 | -5.26 | -8.28 | -16.31 | -12.04 | -10.59 | Upgrade
|
| Minority Interest in Earnings | 0.28 | 0.36 | 0.49 | -0.11 | -0.8 | 0.8 | Upgrade
|
| Net Income | -5.08 | -4.9 | -7.79 | -16.42 | -12.84 | -9.79 | Upgrade
|
| Net Income to Common | -5.08 | -4.9 | -7.79 | -16.42 | -12.84 | -9.79 | Upgrade
|
| Shares Outstanding (Basic) | 17 | 12 | 4 | 3 | 3 | 2 | Upgrade
|
| Shares Outstanding (Diluted) | 17 | 12 | 4 | 3 | 3 | 2 | Upgrade
|
| Shares Change (YoY) | 71.54% | 169.26% | 36.92% | 26.39% | 27.07% | 12.67% | Upgrade
|
| EPS (Basic) | -0.29 | -0.42 | -1.80 | -5.19 | -5.12 | -4.97 | Upgrade
|
| EPS (Diluted) | -0.29 | -0.42 | -1.80 | -5.19 | -5.12 | -5.00 | Upgrade
|
| Free Cash Flow | -2.27 | -1.81 | -4.21 | -7.52 | -7.62 | -4.56 | Upgrade
|
| Free Cash Flow Per Share | -0.13 | -0.15 | -0.97 | -2.37 | -3.04 | -2.31 | Upgrade
|
| Gross Margin | 100.00% | 99.85% | -98.15% | 70.47% | 98.57% | 96.13% | Upgrade
|
| Operating Margin | -615.35% | -923.34% | -4439.24% | -1558.54% | -3290.07% | -1760.87% | Upgrade
|
| Profit Margin | -636.31% | -962.12% | -5109.26% | -1693.50% | -3608.47% | -2026.97% | Upgrade
|
| Free Cash Flow Margin | -284.42% | -355.02% | -2760.64% | -775.23% | -2140.33% | -944.82% | Upgrade
|
| EBITDA | -4.88 | -4.67 | -6.74 | -15.09 | -11.69 | -8.47 | Upgrade
|
| D&A For EBITDA | 0.03 | 0.03 | 0.03 | 0.02 | 0.01 | 0.04 | Upgrade
|
| EBIT | -4.91 | -4.71 | -6.77 | -15.11 | -11.71 | -8.51 | Upgrade
|
Updated Sep 30, 2025. Source: S&P Global Market Intelligence. Standard template. Financial Sources.